A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
- 1 March 2000
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 27 (3) , 145-157
- https://doi.org/10.1016/s0169-5002(00)00094-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- 24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)Lung Cancer, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung CancerChest, 1994
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?Journal of Clinical Oncology, 1993
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Chemotherapy of Lung CancerNew England Journal of Medicine, 1992
- Further evidence in favour of chemotherapy for inoperable non-small cell lung cancerLung Cancer, 1990
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988